Actividades enzimáticas séricas de la ceruplasmina y la mieloperoxidasa en diabéticos tipo 2

Maria de los Angeles Boffill Cárdenas, Ahmed Amaury Ruiz Moré, Elba J, Rodríguez Valcarcel, Jenisey Prada Santana, Evelyn Tejeda Castañeda

Texto completo:

PDF

Resumen

Introducción: La diabetes mellitus tipo 2 se caracteriza por la hiperglucemia debido a la insuficiente producción de insulina de las células β. La mieloperoxidasa promueve el estrés oxidativo durante la inflamación y la ceruloplasmina se considera su inhibidor endógeno.

Objetivo: Evaluar la relación entre la ceruloplasmina y la mieloperoxidasa, determinadas simultáneamente en el suero de pacientes diabéticos tipo 2.

Métodos: Se estudiaron 362 pacientes diabéticos tipo 2 y 110 sujetos sanos. La actividad sérica de la ceruloplasmina se determinó por el método de Siotto; y el de la mieloperoxidasa, por el de Kraeisz.

Resultados: El 72 % de los pacientes diabéticos tenían hiperglucemia y el 77 % presentaba obesidad abdominal. Las actividades de ambas enzimas se incrementaron significativamente en relación con el grupo control. El coeficiente de correlación de la actividad enzimática resultó bajo. El cociente RMPO/CP de los pacientes diabéticos superó el de los controles. La ceruloplasmina no inhibió la mieloperoxidasa.

Conclusiones: Predominó la mieloperoxidasa, por tanto, no se manifestó el efecto inhibitorio de la ceruloplasmina. La elevada actividad de la mieloperoxidasa se asocia con un agravamiento del cuadro clínico del paciente diabético.


Palabras clave

actividad enzimática sérica; ceruplasmina; mieloperoxidasa; diabetes tipo 2.

Referencias

Sasson S. Nutrient overload, lipid peroxidation and pancreatic beta cell function. Free Radic Biol Med. 2017;111:102-9. DOI: https://doi.org/10.1016/j.freeradbiomed.2016.09.003

Bryk AH, Prior SM, Plens K, Konieczynska M, Hohendorff J, Malecki MT, et al. Predictors of neutrophil extracellular traps markers in type 2 diabetes mellitus: associations with a prothrombotic state and hypofibrinolysis. Cardiovasc Diabetol. 2019;18:49. DOI: https://doi.org/10.1186/s12933-019-0850-0

Nagalievska M, Sabadashka M, Hachkova H, Sybirna N. Galega officinalis extract regulate the diabetes mellitus related violations of proliferation, functions and apoptosis of leukocytes. BMC Complement Altern Med. 2018;18:4. DOI: https://doi.org/10.1186/s12906-017-2079-3.

Vashchenko G, MacGillivray RTA. Multi-Copper oxidases and human iron metabolism. Nutrients. 2013;5(7):2289-2313. DOI: https://doi.org/10.3390/nu5072289

Broadley C, Hoover RL. Ceruloplasmin reduces the adhesion and scavenges superoxide during the interaction of activated polymorphonuclear leukocytes with endothelial cells. Am J Pathol. 1989 [acceso 30/10/2019];135(4):647-55. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1880036/

Cabassi A, Binno SM, Tedeschi S, Ruzicka V, Dancelli S, Rocco R, et al. Low serum ferroxidase I activity is associated with mortality in heart failure and related to both peroxynitrite-induced cysteine oxidation and tyrosine nitration of ceruloplasmin. Circ Res. 2014;114(11):1723-32. DOI: https://doi.org/10.1161/circresaha.114.302849

Khan AA, Alsahli MA, Rahmani AH. Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives. Med Sci. 2018;6(2):33. DOI: https://doi.org/10.3390/medsci6020033

Garagiola ML, Tarán M, Scribano MP, Balceda A, García E, Fonseca I, et al. Mieloperoxidasa como indicador de estrés oxidativo en el síndrome metabólico. Rev Arg Cardiol. 2016 [acceso 07/09/2019];84(6):538-42. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=5909255

Abdoa AI, Raynera BS, van Reykc DM, Hawkinsa CL. Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction. Redox Biol. 2017;13:623-32. DOI: https://doi.org/10.1016/j.redox.2017.08.004

Zeng L, Mathew AV, Byun J, Atkins KB, Brosius FC, Pennathur S. myeloperoxidase-derived oxidants damage artery wall proteins in an animal model of chronic kidney disease-accelerated atherosclerosis. J Biol Chem. 2018;293(19):7238-49. DOI: https://doi.org/10.1074/jbc.ra117.000559

Kisic B, Miric D, Dragojevic I, Rasic J, Popovic L. Role of myeloperoxidase in patients with chronic kidney disease. Oxid Med Cell Long. 2016;2016:1069743. DOI: https://doi.org/10.1155/2016/1069743

Teng N, Maghzal GJ, Talib J, Rashid I, Lau AK, Stocker R. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Rep. 2017;22(2):51-73. DOI: https://doi.org/10.1080/13510002.2016.1256119

Chapman ALP, Mocatta TJ, Shiva S, Seidel A, Chen B, Khalilova I, et al. Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J Biol Chem. 2013;288(9):6465-77. DOI: https://doi.org/10.1074/jbc.M112.418970

Yapur VM, Bustos MF, Di Carlo MB, López FN, Vázquez M, Negri GA. Niveles séricos de ceruloplasmina y mieloperoxidasa en pacientes con enfermedad coronaria crónica. Acta Bioquím Clín Latinoam. 2013 [acceso 28/08/2020];47(1):53-9. Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/lil-727423

Cabassi A, Binno SM, Tedeschi S, Ruzicka V, Dancelli S, Rocco R, et al. Myeloperoxidase-related chlorination activity is positively associated with circulating ceruloplasmin in chronic heart failure patients: relationship with neurohormonal, inflammatory, and nutritional parameters. BioMed Res Int. 2015;2015:691693. DOI: https://doi.org/10.1155%2F2015%2F691693

Siotto M, Pasqualetti P, Marano M, Squitti R. Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson’s disease and in hepatic encephalopathy. J Neural Transm (Vienna). 2014;121(10):1281-6. DOI: https://doi.org/10.1007/s00702-014-1196-0

Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterol. 1984 [acceso 28/08/2020];87(6):1344-50. Disponible en: https://pubmed.ncbi.nlm.nih.gov/6092199/

Jha JC, Banal C, Chow BSM, Cooper ME, Jandeleit K. Diabetes and kidney disease: role of oxidative stress. Antiox Redox Signal. 2016;25(12):657-84. DOI: https://doi.org/10.1089/ars.2016.6664

Golizeh M, Lee K, Ilchenko S, Ösme A, Bena J, Sadygov RG, et al. Increased serotransferrin and ceruloplasmin turnover in diet-controlled patients with type 2 diabetes. Free Radic Biol Med. 2017;113:461-9. DOI: https://doi.org/10.1016/j.freeradbiomed.2017.10.373

Tsegyie Y. Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications. Diabetes Metab Syndr Obes. 2020;13:3611-6. DOI: https://doi.org/10.2147/dmso.s275898

Bao X, Borné Y, Johnson L, Muhammad IF, Persson M, Kaijun Niu K, et al. Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the ‘common soil’ hypothesis. Cardiovasc Diabetol. 2018;17(87):87-98. DOI: https://doi.org/10.1186/s12933-018-0733-9

Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atheroscler. 2006;187(2):238-50. DOI: https://doi:10.1016./j. Atherosclerosis.2005.11.035

Mohiuddin SS, Manjrekar P. Role of ceruloplasmin as a low grade chronic inflammatory marker and activated innate immune system in pathogenesis of diabetes mellitus. J Diabetes Metab Disord Control. 2018;5(4):148-53. DOI: https://doi:10.15406/jdmdc.2018.05.00155

Hartman CL, Ford DA. Myeloperoxidase caused endothelial dysfunction: Not so positive it’s about the bleach, it may be a fatal attraction. Arterioscler Thromb Vasc Biol. 2018;38(8):1676-7. DOI: https://doi.org/10.1161/ATVBAHA.118.311427

Strzepa A, Pritchard KA, Dittel, BN. Myeloperoxidase: A new player in autoimmunity. Cell Immunol. 2017;317:1-8. DOI: https://doi.org/10.1016%2Fj.cellimm.2017.05.002

Jelić N, Galijašević S, Lovrić M, Vasilj M, Selak S, Mikulić I. Levels of nitric oxide metabolites and myeloperoxidase in subjects with type 2 diabetes mellitus on metformin therapy. Exp Clin Endocrinol Diab. 2019;6(01):56-61. DOI: https://doi.org/10.1055/a-0577-7776

Qaddoumi MG, Alanbaei M, Hammad MM, Khairi IA, Cherian P, Channanath A, et al. Investigating the role of myeloperoxidase and angiopoietinlike Protein 6 in obesity and diabetes. Sci Rep. 2020;10:6170. DOI: https://doi.org/10.1038/s41598-020-63149-7



Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.